We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

69 hedge funds and large institutions have $122M invested in KalVista Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 21

12.27% more ownership

Funds ownership: 76.96% → 89.23% (+12%)

5% less funds holding

Funds holding: 73 → 69 (-4)

17% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 12

50% less capital invested

Capital invested by funds: $244M → $122M (-$123M)

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

Holders
69
Holders Change
-4
Holders Change %
-5.48%
% of All Funds
1.52%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.04%
New
10
Increased
26
Reduced
21
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$19.9M
2
IC
Ikarian Capital
Texas
+$9.91M
3
O
OrbiMed
New York
+$3.51M
4
Victory Capital Management
Victory Capital Management
Texas
+$3.47M
5
OM
Opaleye Management
Massachusetts
+$3.04M

Top Sellers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
-$3.56M
2
ACP
Acuta Capital Partners
California
-$1.92M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.35M
4
PC
Polar Capital
United Kingdom
-$953K
5
DAM
DLD Asset Management
New York
-$891K
Name Holding Trade Value Shares
Change 		Change in
Stake
SIM
51
Spark Investment Management
New York
$98K +$174K +12,910 New
AllianceBernstein
52
AllianceBernstein
Tennessee
$94K +$29.7K +2,200 +22%
New York State Common Retirement Fund
53
New York State Common Retirement Fund
New York
$92K – – –
Invesco
54
Invesco
Georgia
$83K +$147K +10,884 New
Barclays
55
Barclays
United Kingdom
$82K -$192K -14,217 -57%
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$82K -$2.02K -150 -1%
UBS Group
57
UBS Group
Switzerland
$57K -$133K -9,882 -57%
AIG
58
American International Group
New York
$57K -$5.82K -431 -5%
NFG
59
Next Financial Group
Texas
$36K – – –
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$35.2K +$37.8K +2,803 +156%
Ensign Peak Advisors
61
Ensign Peak Advisors
Utah
$33K -$57.4K -4,253 -50%
Deutsche Bank
62
Deutsche Bank
Germany
$33K -$3.54K -262 -6%
Citigroup
63
Citigroup
New York
$30K +$18.3K +1,357 +54%
Legal & General Group
64
Legal & General Group
United Kingdom
$16K -$4.36K -323 -13%
Rockefeller Capital Management
65
Rockefeller Capital Management
New York
$11K – – –
AIP
66
Ameritas Investment Partners
Nebraska
$8K – – –
Federated Hermes
67
Federated Hermes
Pennsylvania
$2K +$3.59K +266 New
VFA
68
Valeo Financial Advisors
Indiana
$1K – – –
BC
69
Boxer Capital
California
– -$3.56M -200,000 Closed
ACP
70
Acuta Capital Partners
California
– -$1.92M -107,500 Closed
DAM
71
DLD Asset Management
New York
– -$891K -50,000 Closed
Public Sector Pension Investment Board (PSP Investments)
72
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
– -$584K -32,800 Closed
Verition Fund Management
73
Verition Fund Management
Connecticut
– -$553K -31,065 Closed
Millennium Management
74
Millennium Management
New York
– -$501K -28,148 Closed
Goldman Sachs
75
Goldman Sachs
New York
– -$360K -20,213 Closed
1 2
3
4

KALV Hedge Fund Activity: Q1 2020 in Review

69 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2020, worth a combined $122M — down 50% from $244M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of KALV and 10 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 26 added.

The largest buyer was Vivo Capital, opening a new position worth an estimated $19.9M. The largest seller was Boxer Capital, exiting entirely with an estimated $3.56M sold.

  • 69 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2020, down from 73 in Q4 2019.
  • Funds reported $122M of KalVista Pharmaceuticals stock for Q1 2020, down 50% quarter-over-quarter.
  • 10 funds opened new KalVista Pharmaceuticals positions in Q1 2020 and 12 closed out, a net change of -2 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2020 was Vivo Capital, an estimated $19.9M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2020 was Boxer Capital, an estimated $3.56M sold.

Based on aggregated 13F filings for Q1 2020.